Both agents induced a reduction in PD-1 and CTLA4 expression on T cells and of CD200 and BTLA expression, as well as of IL10 production on CLL cells, diminishing the immunosuppressive status induced by CLL cells. The gene discussed is CD200; the disease is B-cell chronic lymphocytic leukemia.